An example is tirzepatide, a dual GLP-1/GIP receptor agonist, which has been approved for both T2D and obesity-management, demonstrating up to 22.5% weight-loss in phase-3 trials. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.